Cargando…
Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population
TURKOVAC™ is a whole-virion inactivated COVID-19 vaccine which was developed and granted emergency use and conditional marketing authorization in December 2021 in Türkiye. The objective of this study is to assess the distribution and the severity of allergic adverse events following the administrati...
Autores principales: | Kara, Ateş, Coskun, Aslihan, Temel, Fehminaz, Özelci, Pervin, Topal, Selmur, Ates, İhsan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958953/ https://www.ncbi.nlm.nih.gov/pubmed/36851314 http://dx.doi.org/10.3390/vaccines11020437 |
Ejemplares similares
-
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials
por: Ozdarendeli, Aykut, et al.
Publicado: (2023) -
Lot quality survey: an appealing method for rapid evaluation of vaccine coverage in developing countries – experience in Turkey
por: Cakir, Banu, et al.
Publicado: (2008) -
Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
por: Tanriover, Mine Durusu, et al.
Publicado: (2022) -
A New Marker to Determine Prognosis of Acute Pancreatitis: PLR and NLR Combination
por: Kaplan, Mustafa, et al.
Publicado: (2018) -
Seasonal Influenza Vaccine Effectiveness in Preventing Laboratory Confirmed Influenza in 2014-2015 Season in Turkey: A Test-Negative Case Control Study
por: Hekimoğlu, Can Hüseyin, et al.
Publicado: (2018)